Possibilities of Azilsartan Medoxomil for Preparation for Planned Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus

Possibilities of Azilsartan Medoxomil for Preparation for Planned Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus

Key Findings

Evaluation of the efficacy and safety of azilsartan medoxomil for preoperative preparation and improving the long-term prognosis of elective percutaneous coronary intervention (PCI) in patients with ischemic heart disease (IHD), arterial hypertension (AH), and type 2 diabetes mellitus (DM).

During the study, it was observed that azilsartan medoxomil showed potential benefits in improving renal function and preventing contrast-induced acute kidney injury (CI-AKI) in patients with IHD, AH, and DM.

Practical Implications

Azilsartan medoxomil demonstrated a significant decrease in glomerular filtration rate (GFR) compared to the control group, indicating its potential in preserving renal function in this patient population.

Patients receiving azilsartan medoxomil showed lower levels of urinary markers of kidney damage, suggesting its potential for prevention of CI-AKI in combination with AH and DM.

Value in Clinical Practice

This study highlights the importance of using new, more sensitive markers of kidney damage for diagnosing CI-AKI and assessing the effectiveness of prevention in patients undergoing PCI with underlying IHD, AH, and DM.

The findings support the potential use of azilsartan medoxomil, particularly in preventing CI-AKI and preserving renal function in patients with IHD, AH, and DM.

For more information on AI-driven solutions and digital healthcare services, visit aidevmd.com.